SCHEMBL4256983

SCHEMBL4256983

CS(=O)(=O)c1ccc(C(=O)Nc2ccc(-c3nc(-c4ccccc4)c(C(F)(F)F)o3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 2/20 0.63
DGAT1 O75907 8/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
PTGS2 P35354 1/20 0.48
MAPT P10636 3/20 0.47
PSMD14 O00487 1/20 0.47
POLB P06746 1/20 0.47
RECQL P46063 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
KDM4E B2RXH2 1/20 0.45
ALOX12 P18054 1/20 0.45
HTT P42858 1/20 0.45
HDAC4 P56524 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261440 0.89 SMO (0.74) SMODGAT1MEN1KMT2ANPC1
SCHEMBL4260410 0.88 SMO (0.68) SMODGAT1NPC1RAB9AMAPT
SCHEMBL4254381 0.87 SMO (0.69) SMODGAT1MEN1KMT2ANPC1
SCHEMBL4263809 0.86 SMO (0.74) SMODGAT1NPC1MAPTKDM4E
SCHEMBL4262412 0.85 SMO (0.64) SMODGAT1MEN1KMT2ANPC1
SCHEMBL4263832 0.85 SMO (0.64) SMODGAT1MAPTPOLBHDAC4
SCHEMBL4257547 0.85 SMO (0.69) SMODGAT1NPC1RAB9AMAPT
SCHEMBL4252955 0.83 SMO (0.64) SMODGAT1MEN1KMT2ANPC1
SCHEMBL4259931 0.83 SMO (0.64) SMODGAT1MAPTTRPV1
SCHEMBL4259960 0.82 SMO (0.66) SMODGAT1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 SMO 1063/4885DGAT1 2723/4885MEN1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.